Back to Articles

What Category 2 Removal Actually Means (And What It Doesn't)

May 1, 20265 min readTruPeptide Editorial

The Misconception Everyone Is Repeating

Since April 15, 2026, when the FDA announced that 12 peptides would exit Category 2, a dangerous misconception has spread across social media, clinic marketing, and even some news coverage:

"The peptides are legal again."

This is wrong. And if you're a patient, provider, or pharmacy acting on this belief, you need to understand why.

What Actually Happened

On April 15, 2026, the FDA announced two things simultaneously:

  1. 12 peptides would be removed from Category 2 (the "significant safety risks" list) effective April 22, 2026
  2. The Pharmacy Compounding Advisory Committee (PCAC) would meet July 23–24, 2026 to evaluate whether 7 of these peptides should be added to the 503A bulks list

The removal happened because the underlying nominations for these compounds were withdrawn — not because the FDA determined they were safe. This is a procedural action, not a safety determination.

The Critical Distinction Nobody Is Making

Here's the part that matters:

Removal from Category 2 does NOT equal authorization to compound.

The FDA's 503A framework has three categories:

  • Category 1 — Sufficient supporting information, eligible for the bulks list. FDA exercises enforcement discretion (meaning pharmacies can compound these under physician prescription).
  • Category 2 — Sufficient information but significant safety risks identified. NOT eligible for enforcement discretion.
  • Category 3 — Insufficient information for review.

When a compound exits Category 2, it doesn't automatically move to Category 1. It enters a regulatory gray zone — no longer restricted, but not yet authorized. The FDA has not indicated it will exercise enforcement discretion for these compounds.

As the law firm Frier Levitt explained in their analysis: "FDA's recent actions should not be understood as authorizing compounding with these peptides under Section 503A."

What the PCAC Meeting Will Decide

The July 23–24 PCAC meeting is where the real decision happens. The committee will evaluate whether to recommend adding 7 peptides to the 503A bulks list:

July 23: BPC-157, KPV, MOTs-c, TB-500 July 24: Emideltide (DSIP), Semax, Epitalon

If the PCAC recommends inclusion AND the FDA accepts that recommendation AND completes the rulemaking process, then — and only then — would these compounds be formally authorized for 503A compounding.

Even a favorable PCAC vote is not the finish line. As AMC Defense Law notes: "A favorable vote does not itself restore legal compounding rights. It only moves the process forward."

What This Means for Patients

If you're currently using or considering peptide therapy:

What you CAN do safely

  • Access FDA-approved peptides (semaglutide, tirzepatide, etc.) through standard prescriptions
  • Access Category 1 compounds through licensed clinics and 503A pharmacies
  • Research compounds through legitimate information sources

What carries risk

  • Assuming Category 2 removal means your clinic can now legally compound BPC-157, TB-500, or Semax
  • Purchasing "research chemicals" from unregulated vendors for personal use
  • Trusting clinics that market these compounds as "now legal" without qualification

What to ask your provider

  • "Is this compound on the 503A bulks list?" (If not, ask about the legal basis for compounding it)
  • "Which pharmacy compounds this, and are they licensed under 503A or 503B?"
  • "Can you provide a Certificate of Analysis for this batch?"

What This Means for Clinics and Pharmacies

The enforcement landscape is shifting but hasn't shifted yet. AMC Defense Law has documented that federal enforcement actions against clinics and pharmacies have continued even as the political rhetoric favors deregulation.

Providers face investigation risk around:

  • Sourcing — Where compounds are obtained
  • Recordkeeping — Prescription documentation
  • Medical necessity — Clinical justification for prescribing
  • Marketing claims — What's promised to patients

The safest position for providers: wait for the PCAC process to complete before expanding peptide offerings beyond Category 1 compounds.

The Political Context

HHS Secretary Kennedy has been vocal about supporting broader peptide access. His public statements have created an expectation of rapid deregulation. But political signals are not regulatory actions.

The prior PCAC panel voted to keep restrictions in place, citing limited human data and safety concerns. A new committee may take a different view — STAT News reports that advisers are expected to be more favorable. But expectations are not outcomes.

The Bottom Line

| What happened | What it means | |---|---| | 12 peptides removed from Category 2 | They're no longer on the "do not compound" list | | PCAC meeting scheduled July 23–24 | 7 compounds will be evaluated for the 503A bulks list | | Political support from HHS Secretary | Favorable signals, but not regulatory action | | What has NOT happened | No compounds have been added to the 503A bulks list. No enforcement discretion has been extended. No compounding has been formally authorized. |

The regulatory process is moving in the right direction. But "moving" and "arrived" are different things. Until the PCAC completes its review and the FDA acts on the recommendations, these compounds exist in a gray zone that carries real legal and safety risk.

We'll have same-day coverage of the July 23–24 PCAC meeting. Follow the FDA Tracker for live updates.

Sources: JD Supra / Frier Levitt, AMC Defense Law, STAT News, FDA Federal Register Notice. Content was rephrased for compliance with licensing restrictions.